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Mutations in the human X-linked cyclin-dependent kinase-like
5 (CDKL5) gene have been identified in patients with Rett syn-
drome (RTT), West syndrome, and X-linked infantile spasms,
sharing the common feature of mental retardation and early sei-
zures. CDKL5 is a rather uncharacterized kinase, but its involve-
ment in RTT seems to be explained by the fact that it works
upstream of MeCP2, the main cause of Rett syndrome. To under-
stand the role of this kinase for nervous system functions and to
address ifmolecularmechanisms are involved in regulating its dis-
tribution and activity, we studied the ontogeny of CDKL5 expres-
sion in developingmouse brains by immunostaining andWestern
blotting.The expressionprofile ofCDKL5was comparedwith that
of MeCP2. The two proteins share a general expression profile in
the adultmouse brain, but CDKL5 levels appear to be highlymod-
ulated at the regional level. Its expression is strongly induced in
early postnatal stages, and in the adult brain CDKL5 is present in
mature neurons, but not in astroglia. Interestingly, the presence of
CDKL5 in the cell nucleus varies at the regional level of the adult
brain and is developmentally regulated. CDKL5 shuttles between
thecytoplasmandthenucleusandtheC-terminal tail is involved in
localizing the protein to the cytoplasm in amechanism depending
on active nuclear export. Accordingly, Rett derivatives containing
disease-causing truncations of the C terminus are constitutively
nuclear, suggesting that they might act as gain of function muta-
tions in this cellular compartment.
Rett syndrome (RTT,3 OMIM 312750) is an X-linked neuro-
developmental disorder that occurs almost exclusively in girls
with an incidence of 1:10,000 female births. Patients affected
with classic RTT are usually born healthy and start manifesting
symptoms after an apparently normal period of development
lasting 6–18 months (1, 2). Then a rapid regression causes the
loss of speech and purposeful movements and the appearance
of autistic traits, ataxia, seizures, scoliosis, respiratory crisis,
and characteristic stereotypic hand movements. Furthermore,
decelerated head growth is typically present, leading to micro-
cephaly within the second year (3). Despite the reduced brain
volume, no diminution in neuronal number has been observed,
but rather a decrease in cell soma size and dendritic arboriza-
tion. Approximately 25% of RTTpatients are characterized by a
clinical picture that does not completely meet the accepted
diagnostic criteria; accordingly, several RTT variant forms have
been described differing in disease onset and severity (4).
Defects in the methyl-CpG-binding protein 2 (MECP2) and
cyclin-dependent kinase-like 5 (CDKL5) genes, located on
Xq28 and Xp22, respectively, have been identified as genetic
causes of RTT (5–11). Mutations in MECP2 account for more
than 95% of patients with classic RTT but have been found in
only 20–40% of atypic RTT patients (12). CDKL5 defects have
been found in some patients with the Hanefeld variant, a con-
genital form of RTT characterized by the presence of intracta-
ble seizures during the firstmonths of life (7–11, 13).Moreover,
mutations or chromosomal translocations involving CDKL5
have also been identified in patients with infantile spasms asso-
ciated with mental retardation and in West syndrome patients
(14–16).
MeCP2 is a transcriptional repressor that binds methylated
CpGs in the mammalian genome and silences gene expression
through the recruitment of corepressor complexes containing
different chromatin modifying activities (17–19). The current
model explaining RTT onset in patients with MECP2 muta-
tions suggests that defects occur in the nervous system due to
the deregulation of a number of neuronal genes (20). Accord-
ingly, among other genes, MeCP2 has been shown to regulate
the expression of the brain-derived neurotrophic factor (Bdnf)
gene in an activity-dependent manner regulated by the specific
phosphorylation of the methyl-binding protein (21–23). How-
ever, since the efforts to identify MeCP2 target genes have not
been able to justify the dramatic phenotype associated with the
lack of the methyl-binding protein, some authors have pro-
posed that MeCP2 functions other than transcriptional repres-
sion might play a role in RTT. Accordingly, it has been demon-
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strated thatMeCP2 is also involved in regulation of splicing and
that aberrant alternative splicing patterns are observed in a
mouse model of Rett syndrome (24). Furthermore, the large-
scale mapping of neuronal MeCP2 sites has revealed the pres-
ence of MeCP2 on a large number of active promoters, an
observation, which has recently been reinforced by Ishibashi et
al. (25, 26). Eventually, very lately it has been proposed that
MeCP2 not only works as a repressor but also as an activator of
transcription and that, at least in the hypothalamus, the activat-
ing functions are predominant (27).
The human CDKL5 gene encodes a protein of 1030 amino
acids with an N-terminal catalytic domain highly homologous
tomembers of themitogen-activated protein (MAP) kinase and
cyclin-dependent (CDK) kinase families (28). The protein is
rather uncharacterized but its involvement in RTT has been
explained by the fact that this kinase seems to function in a
molecular pathway common to that of MeCP2 (11, 29). In fact,
the two proteins form a protein complex in vivo and the cata-
lytic activity of CDKL5 mediates the phosphorylation of
MeCP2 in vitro. Moreover, the two genes share temporal and
spatial expression patterns in the brain and are simultaneously
activated during neuronal maturation (11). According to the
current model, CDKL5 works upstream of MeCP2 influencing
directly or indirectly its phosphorylation state and thereby spe-
cific functions of the methyl-binding protein. In the absence of
CDKL5, these phosphorylation-dependent activities of MeCP2
would be altered causing a subset of Rett symptoms. In addi-
tion, other as yet non-discovered targets of the kinase would
also be deregulated, leading to the specific phenotype associ-
ated with CDKL5 mutations. In agreement with this model, so
far, RTT causing mutations in CDKL5 have been found only in
patients with the Hanefeld variant and never associated with
classic RTT. The fact that the autonomous nervous system,
whose malfunction in patients with MECP2 mutations causes
severe respiratory problems and constipation, appears to be
better preserved in patients withCDKL5 deficits reinforces also
separate functions of the two proteins (30).
Whereas substantial information has been gathered regard-
ing the expression and localization of theMeCP2 protein in the
nervous system, CDKL5 remains completely uncharacterized.
MeCP2 is expressed in the embryonic brain but its levels
increase significantly during late embryonic stages reaching
levels that remain rather uniform during postnatal develop-
ment where the methyl-binding protein is found in the nucleus
of most neurons of the adult brain (31–35). The induction of
MeCP2 expression follows that of neuronalmaturation, and the
precise protein levels have shown to be crucial for correct syn-
apse formation (23).
To better understand the role of CDKL5 in the nervous system
and to understand when and where it might enter in contact
with themethyl-binding protein, we have analyzed in detail the
expression profile of this kinase in embryonic and postnatal
brains from normal mice and compared it to that of MeCP2.
Our data demonstrate that despite an expression profile gener-
ally overlapping that of MeCP2, CDKL5 peaks later in develop-
ment, and its levels appear to be much more modulated than
those of MeCP2. Furthermore, whereas MeCP2 is an exclu-
sively nuclear protein, CDKL5 shuttles between the two main
cellular compartments and the relative concentrations in each
compartment seem to vary in different brain areas and during
development. Eventually, we demonstrate that the C-terminal
region of CDKL5, which is frequently deleted in pathogenic
mutations, is involved in an active nuclear export mechanism
modulating the subcellular distribution of the kinase.
EXPERIMENTAL PROCEDURES
Cell Cultures—Astroglial cell cultures were prepared from
newborn mice. Using a sterile technique, the animals were
decapitated, the brains were removed and placed in Petri dishes
containing PBS and penicillin-streptomycin. The cortical tissue
was separated from themeninges and dissociated by trituration
with a Pasteur pipette. Cells were grown in T75 flasks contain-
ing DMEM (Invitrogen) supplemented with 10% fetal calf
serum and 2 mM glutamine. Cultures were kept at 37 °C in a
humidified 5% CO2 atmosphere. The medium was changed
every 3 days. Astroglial cell cultures consisted of "90% glial
fibrillary acidic protein-positive cells, #1% neurons, and #3%
microglial cells.
Primary neuronal cultures were prepared from the cortex of
day 17.5mouse embryos (E17.5). Briefly, cortical cells were dis-
sociated and centrifuged at 800 rpm for 5 min, resuspended in
DMEMwith 10% horse serum (HS, Invitrogen) by gentle tritu-
ration with a Pasteur pipette and plated at 45.000 cells/cm2 in
modified DMEM-HS on poly-D-lysine-coated glass coverslips
(Sigma-Aldrich). After 3 h, themediumwas replacedwithNeu-
robasal medium containing B27 supplement (Invitrogen) and 2
mM glutamine, and incubated at 37 °C in a humidified incuba-
tor with 5% CO2 for 10 days. Human HeLa cells were main-
tained in DMEM supplemented with 10% fetal calf serum at
37 °C with 5% CO2. Leptomycin B treatment was performed
with 50 nM LMB for 3 h prior to fixation.
Plasmids—GFP-hCDKL5 was described previously (29);
GFP-$941 (amino acids 1–941), GFP-$831 (amino acids
1–831), GFP-832–1030 (amino acids 832–1030), GFP-L879X
(amino acids 1–878), and GFP-R781X (amino acids 1–780)
contain the indicated regions of hCDKL5 cloned into the
BamHI site of pEGFP-C1 (Clontech). All constructs were gen-
erated by PCR and sequence-verified.
Antibodies—A rabbit anti-MeCP2 anti-serum (Covance
Research Product Inc.) was raised against hMeCP2 (amino
acids 171–486) expressed in Escherichia coli as a fusion protein
containing a chitin-binding domain that was eliminated during
the purification procedure. This antibody was used 1:1000. For
some experiments, a polyclonal anti-MeCP2 antibody (Sigma,
1:1000) was used.
Moreover, the following antibodies were used in Western
blotting, immunohistochemistry, and/or immunofluorescence
experiments: rabbit polyclonal anti-CDKL5 (1:1000 inWestern
blotting in Figs. 1 and 5; when purified against the antigen span-
ning amino acids 301–751 the antibody was used 1:50 inWest-
ern blotting (Figs. 2, 4, and 6) and 1:5 in immunofluorescence
and immunohistochemistry experiments; Covance Research
Product Inc.; Ref. 29), mouse monoclonal anti-GABA (1:200,
Sigma); mouse monoclonal anti-NeuN (1:100, Chemicon);
anti-MAP2 (1:200, Sigma), anti-GAPDH (1:2000, Open BIO-
SOURCE), and anti-actin (1:5000, Sigma).
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Immunohistochemistry—For immunohistochemistry exper-
iments, C57BLJ6micewere used.Newbornmice (P0), andmice
of postnatal stages 12.5 (P12.5), and P120 were anesthetized by
intraperitoneal injections of chloral hydrate, and the brains
were fixed by intracardiac perfusion with NaCl 0,9%, followed
by 4% paraformaldehyde (PFA) in PBS. Brains were removed
and postfixed for 4–6 h in 20% sucrose in 4% PFA at 4 °C,
placed in 20% sucrose in PBS overnight and frozen in dry ice.
Cryostat sections were cut in the saggital or coronal plane at 20
"m and rinsed three times in PBS. Sections were incubated for
1 h at room temperature in 10% goat serum (Sigma) and 0,5%
Triton X-100 (Sigma) in PBS, then incubated with the primary
antibody overnight at 4°C in the same solution. The next day,
sections were rinsed three times and incubated at room tem-
perature for 1 h in a secondary antibody solution of biotinylated
goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA) at
1:200 in PBS. After three washes, sections were incubated with
the avidin-biotin complex in PBS for 1 h using the Vectastain
Elite ABC kit, washed three times and the staining visualized by
incubation with 0.5 mg/ml 3,3!-diaminobenzidine tetrahydro-
chloride (Sigma) and 0.3 "l/ml hydrogen peroxide in PBS. Sec-
tions were dehydrated in ascending alcohols andmounted with
DPX mounting media. To control for the specificity of the sig-
nal, sectionswere run through the entire procedure butwithout
the incubation with the primary antibodies.
The human brain samples are an autopsy from a postmortem
brain and an operatory biopsy, respectively, from two adult
women (ages 63 and 21 years old). Five micrometer sections
were cut from the formalin-fixed and paraffin-embedded tissue
and used for immunohistochemistry experiments following the
above procedures.
Immunofluorescence—Human HeLa cells were seeded on
gelatin-coated glass coverslips and transiently transfected with
Lipofectamine 2000 (Invitrogen). 16-h post-transfection, the
cells were fixed with 4% PFA, stained with 4!,6-diamidino-2-
phenylindole dihydrochloride (DAPI; Sigma), and the specific
GFP signals analyzed with an Olympus BX51 Fluorescence
microscope.
For fluorescent double labeling, free-floating brain sections
from adult C57BLJ6 mice or primary cortical neurons were
stained. After 1 h in blocking solution (PBS, 5% fetal bovine
serum, 0.5% Triton X-100), sections were incubated overnight
at 4 °C with the primary antibody. Sections were rinsed three
times in PBS and incubated with Alexa 555 goat anti-rabbit IgG
antibody (1:2000, Molecular Probes) and Alexa 488 goat anti-
mouse IgG antibody (1:2000,Molecular Probes) for 1 h at room
temperature. After nuclear staining with DAPI for 5 min, they
were mounted on glass slides and coverslips were applied using
Moviol (Sigma) mounting medium. The slides were analyzed
on an Olympus BX51 Fluorescence microscope.
Mouse primary neurons were grown for 10 days in vitro and
fixed with 4% PFA. After 10 min in permeabilization solution
(HEPES 20 mM pH 7.4, sucrose 300 mM, MgCl2 3 mM, Triton
X-100 0.2%) and 15min in PBS, 5% fetal bovine serum, cells were
incubated overnight at 4 °C with primary antibodies in PBS, 5%
fetal bovine serum, and0.2%TritonX-100.Cellswere rinsed three
times, incubated with secondary antibodies, the nuclei stained
withDAPI for 5min, and the coverslipsmounted formicroscopy.
Protein Extraction and Western Blotting—Brain tissue frac-
tionation was performed as follows. Differently aged CD1mice
were killed, brains or carefully dissected brain areas were rap-
idly explanted on ice, and homogenized in cytosolic lysis buffer
(HEPES pH 7.5 20 mM; MgCl2 1.5 mM; KCl 10 mM; dithiothre-
itol 2 mM) by 50 strokes with an automatic Potter. A protease/
phosphatase inhibitor mix (Na3VO4 1 mM; phenylmethylsulfo-
nyl fluoride 1 mM; protease inhibitor mixture (Roche Applied
Sciences); NaF 1 mM) was used in all the buffers. Homogenates
were centrifuged at 2000 % g at 4 °C for 5 min, and the super-
natant was collected as the cytosolic fraction. The nuclei were
washed oncewith cold PBS, lysed in nuclear lysis buffer (HEPES
pH 7.5 20mM;MgCl2 1.5mM;NaCl 420mM; SDS 1%; EDTA 0,2
mM; glycerol 25%; dithiothreitol 2 mM) and incubated for 30
min at 100 °C. After incubating overnight on a wheel at room
temperature, samples were centrifuged at 20,000 % g for 30
min. The supernatant was recovered as the nuclear fraction. In
parallel, total lysates were prepared homogenizing brain and
cerebellar tissues in total lysis buffer (HEPES pH 7.5 20 mM;
MgCl2 1.5 mM; NaCl 420 mM; EDTA 0.2 mM; glycerol 25%;
dithiothreitol 2 mM), adding SDS 1% and proceeding as for
nuclear lysis. The protein content was dosed by bicinchonic
acid assay (Pierce). Samples were conserved in Laemmli buffer
and processed by immunoblotting.
For Western blotting, the proteins were separated on 10%
SDS-PAGE, transferred to nitrocellulose membranes, and the
blots incubated with antibodies against MeCP2, CDKL5,
GAPDH, and/or actin. A Kodak Image Station 2000R was used
to quantify the signals.
RESULTS
As already mentioned, recent clinical and biochemical data
suggest that CDKL5 belongs to the same molecular pathway as
MeCP2 (11, 29); however, it remains unknown in which brain
area(s) and developmental stages this functional interaction
should occur.We therefore performed immunohistochemistry
experiments to study the expression profile of CDKL5 inmouse
brains and compared it at the regional level to that of MeCP2.
As shown in Fig. 1, in the adult mouse brain the two proteins
showed very similar expression patterns, which is consistent
with the fact that theywork in a commonmolecular pathway. In
fact, both CDKL5 and MeCP2 are diffusely expressed in all the
brain structures analyzed at adult stages. Both proteins could be
detected in the cerebral cortex (Fig. 1, panels A, E, I, and M),
hippocampus (Fig. 1, panels B, F, J, and N), cerebellum (Fig. 1,
panels C,G,K, andO), and brain stem (Fig. 1,panelsD,H,L, and
P). Therefore, these immunohistochemistry experiments
revealed a similar dispersed but consistent expression of both
proteins in virtually all cells of the different brain areas. In a
parallel approach, by Western blotting on whole cell lysates
obtained from carefully dissected brain areas, we compared
MeCP2 and CDKL5 protein levels in the different brain dis-
tricts. The signal corresponding toCDKL5 andMeCP2, respec-
tively, were normalized to GAPDH levels, and the relative
amounts illustrated in Fig. 1R. As seen in theWestern blot (Fig.
1Q), MeCP2 levels appear rather uniform among the different
areas except the cerebellum where it is highly expressed.
CDKL5 levels are, on the other hand, more modulated; in fact,
Modulation of CDKL5 Expression during Neuronal Development
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whereas significant amounts of CDKL5 are found in the adult
hippocampus, cortex, thalamus, and striatum (Fig. 1Q, lanes 1,
2, 4, and 5), the levels of the kinase appear more reduced in the
hypothalamus and cerebellum (lanes 3 and 6). This is in accord-
ance with the immunohistochemis-
try experiments where CDKL5
appeared less intense but with sig-
nificant expression in granular (GL)
and Purkinje (PL) cells (Fig. 1, pan-
els C, G, and K, O).
MeCP2 has been reported to be
expressed in late embryonic and
early postnatal stages where its pro-
file correlates with neuronal matu-
ration (31, 34). To understand the
dynamics of CDKL5 expression, we
compared the pattern of the two
proteins in the cortex and hip-
pocampus at embryonic day 16.5
(E16.5), newborn (P0), postnatal
days 12.5 and 120 (P12.5 and P120,
respectively). As reported previ-
ously, MeCP2 is expressed rather
uniformly in the cortex already at
E16.5; in early postnatal stages its
expression gets modulated, though,
and in adult stages the protein levels
are higher in layer V correlating
with highest levels in more mature
neurons (31, 33, 34). Surprisingly,
CDKL5 presented a developmental
expression profile very similar to
that described for MeCP2. In fact,
CDKL5 was only minimally detect-
able at embryonic stage E16.5 (Fig.
2, panel A) while it was induced in
maturing neurons residing in the
cortical plate (cp) at perinatal stages
(Fig. 2, panel B). During the follow-
ing postnatal development, CDKL5
gets strongly up-regulated in both
cerebral cortex and hippocampus
(Fig. 2, panels C, D, F, and G). To
summarize, the immunohisto-
chemistry experiments indicate
that CDKL5 expression is very low
in abundance in the embryonic cor-
tex and is strongly induced in early
postnatal stages. To confirm this
observation, we performedWestern
blotting on total brain extracts
obtained from mice at different
embryonic and postnatal stages. As
can be seen in Fig. 2 (panels O and
P), these experiments confirmed
that CDKL5 is very low in abun-
dance (but not absent, see Fig. 6,
panel A) in the brain of mouse E18
embryos and is induced in early postnatal stages. A quantifi-
cation of the obtained data indicates that, in the brain,
CDKL5 is expressed at maximum levels at P14 and then
declines slowly up to adult stages (data not shown). In con-
FIGURE1.CDKL5 levels varybetween the individualbrainareasofP120mice.A–P, immunohistochemistry
experiments showing CDKL5 and MeCP2 expression in serial sections of an adult mouse brain (P120). The
different panels show: cortex (A, E, I,M), hippocampus (B, F, J, N), cerebellum (C, G, K,O), and pons (D, H, L, P) of
the adult mouse brain (P120). Panels E–H andM–P are magnifications of A–D and I–L, respectively. I-VI (panels
A and I) indicate the different cortical layers; Dg, dentate gyrus; H, hilus; GL, granule cell layer; PL, Purkinje cell
layer; MC, molecular cell layer. Q, Western blot showing CDKL5 and MeCP2 protein levels (upper and middle
panels, respectively) in whole cell lysates prepared from dissected areas of a P120 brain. GAPDH was used as
loading control (lower panel). R, graphic illustration showing the relative CDKL5 and MeCP2 levels (upper and
lower graph, respectively) in hippocampus (Hip.), cortex (Ctx.), hypothalamus (Hyp.), thalamus (Th.), striatum
(Str.), and cerebellum (Cer.) of the P120 mouse brain. CDKL5 and MeCP2 levels in the Western blot (panel Q)
were normalized to GAPDH setting cortical levels arbitrarily to 1. Scale bars: A, I, D, L& 300 "m; B, J& 500 "m;
C, K& 800 "m; E, H,M, p& 30 "m; G, O& 50 "m.
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trast, and in accordance with published results, MeCP2 lev-
els are rather constant from E18 to adult stages. In the cere-
bellum, the expression of CDKL5 appears to be induced
slightly later and continues to increase until adult stages.
Concerning MeCP2, we observed a significant increase dur-
ing late postnatal development.
Because CDKL5 deficiency has a
strong impact on human brain
functions, we wondered how the
protein was localized in human
adult brain tissues. Immunohisto-
chemistry experiments revealed
numerous and diffusely CDKL5-
positive cells in both the cerebral
cortex and corpus callosum with a
general pattern very similar to that
observed in the adult mouse brain
(Fig. 3, panels A–D). Furthermore,
in the human cerebellum, CDKL5
was detected in the majority of the
cells corresponding to granular,
molecular, and Purkinje cell layers,
although increased levels were pres-
ent in Purkinje neurons in agree-
ment with what was described
above in the murine cerebellum.
Even though MeCP2 has always
been reported to be a neuron-spe-
cific protein, an MeCP2-enhanced
green fluorescent protein reporter
mouse line obtained by knocking in
the EGFP cDNA in theMecp2 locus
has recently permitted to demon-
strate the presence ofMeCP2, at low
levels, in differentiated GFAP-posi-
tive cells (36).We therefore decided
to exploit immunofluorescence and
Western blotting assays to address
which cells express CDKL5. Fig. 4,
panels A–C and E, clearly demon-
strate that virtually all NeuN-posi-
tive neurons express CDKL5; in
contrast, we were unable to detect
CDKL5 inGFAP-positive cells (data
not shown). Accordingly, aWestern
blotting assay performed on awhole
cell extract prepared from cultured
primary astrocytes did not reveal
anyCDKL5 expression (Fig. 4, panel
D), suggesting that the kinase is vir-
tually absent or of very low abun-
dance in the glia.
The above experiments show that
CDKL5 is expressed in the majority
of the neuronal fraction regardless
the neural origin taken into analysis.
It appears however, that some neu-
rons display increased levels of
CDKL5. In particular, in the dentate gyrus, GABAergic cortical
interneurons within the hilus express CDKL5 much stronger
than the dentate granular neurons (Fig. 4, panels F–H). Simi-
larly, in the cerebellum, Purkinje cells express significantly
more CDKL5 than the granular or stellate cells (panels L–N).
These results indicate that CDKL5 levels are finely tuned in
FIGURE 2. CDKL5 expression is highly induced at early postnatal stages of brain development.
A–G, immunohistochemistryexperimentsshowingCDKL5expression inthecortex (A–D) andhippocampus(E–G)of
mouse brains at the indicated embryonic or postnatal stages. H–N, MeCP2 expression in the cortex (H–K) and
hippocampus (L--N) of mouse brains at different developmental stages. CP, cortical plate; IZ, intermediate
zone; VZ, ventral zone; Hi, hippocampus;Dg, dentate gyrus; I-VI, different cortical layers.O and P,Western blot
showingCDKL5 andMeCP2protein levels (upper andmiddle panels, respectively) in total brain (O) or cerebellar
(P) extracts at E18, P2, P5, P14, P28, and P120 stages. Actinwas used as loading control (lower panel). Scale bars:
A–D, H–K& 500 "m; E–G, L–N& 500 "m.
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different neuronal populations, suggesting that a strict control
of CDKL5 levels is required to regulate specific neuronal activ-
ities. In accordancewith these results, we also observe that even
if CDKL5 is present in both glutamatergic and GABAergic pri-
mary cultured neurons, the expression levels are highest in the
latter cell population (data not shown).
Eventually, immunofluorescence experiments were used to
analyze the distribution of endogenous CDKL5 in cultured pri-
mary cortical neurons. As indicated in Fig. 4, panels R–T, a
significant part of endogenous CDKL5 is present in the nucleus
where it shows a typical dotted staining; interestingly a signifi-
cant fraction of CDKL5 is localized in the dendrites.
In the above experiments it emerges that endogenous
CDKL5 is significantly expressed in both nucleus and cyto-
plasm of cultured cortical neurons and in different neurons
throughout the brain. Therefore, we decided to analyze
whether the subcellular distribution of the protein might be
regulated and vary during development. Cytoplasmic and
nuclear extracts were prepared from different brain areas and
analyzed by Western blotting using GAPDH and MeCP2 as
markers of the cytoplasmic and nuclear fractions, respectively.
As shown in Fig. 5A, and illustrated graphically in Fig. 5B, an
almost equal distribution of CDKL5 between cytoplasm and
nucleus is found only in some regions; in fact, in the hippocam-
pus, cortex, hypothalamus, and thalamus,#40% of the protein
is nuclear. Conversely, in the striatum and cerebellum the cyto-
plasmic fraction accounts for almost 80% of CDKL5. These
results show that not only do the total levels of CDKL5 vary
between different brain areas but, importantly, also that the
specific distribution of the protein between the twomain cellu-
lar compartments differs. To investigate whether the subcellu-
lar distribution of CDKL5 is regulated also during development
we analyzed byWestern blotting cytosolic and nuclear extracts
fromwhole brains at different developmental stages using actin
as a loading control. In theWestern
blot in Fig. 6A and the graphic illus-
tration in Fig. 6B, it appears that
CDKL5 in late embryonic and early
postnatal stages is predominantly
cytoplasmic with less than 20% of
the protein being present in the
nucleus (lanes 7–9). In P14 brains,
however, the nuclear fraction in-
creases to #40% and remains as
such until adult stages (lanes
10–12). This dynamic distribution
of CDKL5 is opposed to that of
MeCP2, which appears to be pre-
dominantly nuclear at all develop-
mental stages with a small cytoplas-
mic fraction in late embryonic and
the earliest postnatal stages. Sum-
marizing the obtained data, we sug-
gest that whereas MeCP2 exerts its
functions mainly, if not exclusively,
in the cell nucleus, the subcellular
distribution of CDKL5 depends on
the physiological state of the cell.
The above results clearly indicate that regulatory mecha-
nisms modulate the subcellular localization of CDKL5 in
murine brain development. Active nuclear export mechanisms
depending on nuclear export receptors are responsible for driv-
ing many nuclear proteins to the cytoplasm. Nuclear export
mediated by the receptor CRM1/Exportin 1 is sensitive to the
drug leptomycin B (LMB; 37); to test whether CDKL5might be
actively exported from the nucleus through a CRM1-depend-
ent pathway we analyzed the subcellular localization of
hCDKL5 fused to GFP (GFP-CDKL5) in human HeLa cells
treated or not with LMB. As shown in Fig. 7A, GFP-CDKL5 is
found in both the nucleus and cytoplasm in the majority of
untreated HeLa cells even if the overall situation is rather het-
erogenous with some cells expressing the protein solely in the
nucleus or cytoplasm, respectively; on the other hand, we
observed that after 3 h of treatmentwith 50 nMLMB, themajor-
ity of the protein had accumulated in the nucleus (Fig. 7A, pan-
els a and b, respectively). Interestingly, CDKL5 has a distinct
dotted staining in the nucleus as well as in the cytoplasm; the
nature of these dots will be revealed by future experiments. The
pan-cellular localization of GFP alone was not sensitive to LMB
whereas aGFP fusion protein, used as positive control, contain-
ing bona fide nuclear export and import signals accumulated
significantly in the nucleus of LMB-treated cells (data not
shown). To map the region within CDKL5 involved in this
LMB-sensitive cytoplasmic localization, we tested the subcel-
lular localization of two derivatives of the kinase progressively
deleted in theC-terminal region as illustrated graphically in Fig.
7C. Whereas the deletion of the region spanning amino acids
942–1030 (GFP-$941) did not influence the localization of the
fusion protein, aCDKL5derivative lacking themostC-terminal
200 amino acids (GFP-$831) was confined to the cell nucleus,
demonstrating that a signal for LMB sensitive cytoplasmic
localization of CDKL5 is present in this region (Fig. 7A, panels c
FIGURE 3. CDKL5 has a diffuse expression inmost cells of the adult human brain. Immunohistochemistry
experiments showingCDKL5expression in cerebral cortex (AandB), corpus callosum (CandD), andcerebellum
(E–H) of adult humanbrain.Arrows indicate someCDKL5-positive cells. PCL, Purkinje cell layer;GCL, granule cell
layer;MCL, molecular cell layer. Scale bars: A, C, E, G& 30 "m; B, F& 10 "m; D, H& 20 "m.
Modulation of CDKL5 Expression during Neuronal Development
30106 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 44•OCTOBER 31, 2008
 a
t U
N
IV
. O
F
 IN
S
U
B
R
IA
 o
n
 N
o
v
e
m
b
e
r 1
7
, 2
0
0
8
 
w
w
w
.jb
c
.o
rg
D
o
w
n
lo
a
d
e
d
 fro
m
 
and e, respectively). When the very
C-terminal tail spanning amino
acids 832–1030 of CDKL5 was
fused to GFP (GFP-832–1030) we
observed that the chimeric protein
was excluded from the nucleus and
that the addition of LMB to the cells
did not cause a nuclear accumula-
tion of the protein (Fig. 7A, panels g
and h, respectively). We suppose
that the fusion protein cannot enter
the nucleus due to the absence of a
signal for nuclear import and its size
of #52 kDa, probably rendering it
too big for passing the nuclear
membrane by passive diffusion. In
accordance with CDKL5 being able
to enter the nucleus, the Scan-
Prosite program identifies twoputa-
tive nuclear localization signals
positioned at 312–315 and 784–
789, respectively, both missing in
this construct. The signal located
between amino acids 784–789
proved to be sufficient for localizing
GFP to the cell nucleus (data not
shown), and we believe that the
nuclear localization of GFP-$781
(see below) is due to the presence
of the more N-terminal signal at
312–315.
CRM1-mediated nuclear export
depends on export signals (NES)
within the substrates (37). An
inspection of the primary structure
of CDKL5 revealed the presence of a
stretch of amino acids from 836 to
845 (LKSLRKLLHL) sharing high
homology with the consensus NES
(LX(2,3)[LIVFM]X(2,3)LX[LI]; 38).
To test whether the putative NES
per semight be able to direct nuclear
export of a heterologous protein, we
fused the region containing amino
acids 832–879 to GFP (GFP-(832–
879)) and expressed the protein in
HeLa cells. In this case, however, we
observed a similar pan-cellular dis-
tribution of both GFP and GFP-
(832–879) (data not shown). Fur-
thermore, the substitution of three
leucines with alanines, which is nor-
mally sufficient to inhibit the activ-
ity of a functional NES, did not alter
the subcellular localization of GFP-
CDKL5 (data not shown). These
results indicate that the leucine-rich
sequence within the C-terminal tail
FIGURE 4. CDKL5 is a pan-neuronal protein in the adult mouse brain. A–C and E, Immunofluorescence
experiments showing CDKL5 expression in cortical NeuN-positive neurons of a P120 mouse brain; D, Western
blot showing CDKL5 and MeCP2 expression in whole cell extracts of cultured primary cortical neurons and
astrocytes; F–N,CDKL5expression inhippocampus (F–K) andcerebellum (L–N) is particularly high inGABAergic
neurons (G, J,M);O–Q,CDKL5 colocalizeswithMAP2-positive dendrites of neuronswithin the striatum. Panel E
is a magnification of panel C. Panels C, E, H, K, N, andQ aremerged images of CDKL5 (A, F, I, L, andO) and NeuN
(B), GABA (G, J,M), andMAP2 (P), respectively. R and S, immunofluorescence of endogenous CDKL5 in primary
cortical neurons (R; 10DIV). DAPI staining is shown in panel S and the merge in panel T. Scale bars: A–C, F–H&
150 "m; E, I–Q& 30 "m; R–T& 40 "m.
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of CDKL5 might not be sufficient to be recognized by the
nuclear export receptors and that the LMB-sensitive cytoplas-
mic localization of the kinase is due to an indirect mechanism.
Our data therefore suggest that the subcellular distribution
of CDKL5 is modulated through active import and export
mechanisms and that the long C-terminal tail is the domain
mainly involved in this regulation. However, our previous pub-
lication suggested that the nucleo-cytoplasmic distribution of
CDKL5 depends also on its catalytic activity; these results have
been confirmed using the kinase-dead K42R derivative that,
compared with the wild-type protein, is characterized by a neg-
ligible nuclear fraction (Ref. 29 and data not shown).
Eventually, considering that several pathological truncations
occur in the C-terminal region of CDKL5, we reasoned that
some of themmight alter its subcellular localization.We there-
fore analyzed the subcellular localization of two RTT CDKL5
derivatives deleted within the C-terminal region (L879X and
R781X), respectively, containing or not the putative NES.
When these two derivatives, fused to GFP, were overexpressed
in humanHeLa cells we observed a nuclear localization of both
fusion proteins (Fig. 7B). These data reinforce the role of the
veryC-terminal region in localizing thewild-type protein to the
cytoplasm; furthermore, in accordance with the above data,
they demonstrate that the leucine-rich NES-like signal span-
ning amino acids 836–845 and present in the L879X derivative
is not solely responsible for localizing CDKL5 to the cytoplasm.
DISCUSSION
During the last few years, mutations in the X-linked CDKL5
gene have been identified in a number of patients with severe
encephalopathy and early onset of epilepsy. To date, disease
causing mutations have been identified in 29 patients with
X-linked infantile spasms, atypical Rett syndrome, and infantile
spasms (7–11, 14–16). The common feature describing these
patients is the appearance of epilepsy during the very firstweeks
of life and a developmental delay without any period of normal
development; in many cases the epilepsy becomes refractory to
treatment during later stages (39). The majority of mutations
have been identified in the so-called Hanefeld variant of RTT,
which as opposed to classic RTThas never been associatedwith
mutations in MECP2 (7–11). In accordance with the above
description, the occurrence of early seizures characterizes the
Hanefeld variant; moreover, the absence of respiratory prob-
lems and constipation in many patients with this RTT variant
indicates a better preservation of the autonomous nervous sys-
tem in patients with CDKL5mutations as compared with those
with loss of MeCP2 functions (30).
Even if the above data clearly indicate an important role of
CDKL5 for nervous system functions, the protein remains
largely uncharacterized. The spectrumof disease causingmuta-
tions identified so far include missense mutations within the
catalytic domain, deletions, insertions, or nonsense mutations
causing the premature termination of the protein distributed in
the entire open reading frame, and, finally, deletions of genomic
regions including the entire CDKL5 locus. Attempts to draw a
correlation between mutation type and disease severity are still
hampered by the rather few patients with mutations in CDKL5
and the limited knowledge of its role in the nervous system and
how its activities are regulated. The establishment of a geno-
type-phenotype correlation necessitates therefore that we gain
more insight into the neuronal functions of CDKL5.
In this study we examined the expression pattern of the
CDKL5 protein in the developingmouse brain and compared it
to that of MeCP2, which is the only known substrate of the
kinase identified so far (11, 29). Previous in situ hybridization
FIGURE 5. The subcellular distribution of CDKL5 varies between the indi-
vidual areas of the adult mouse brain. A, fractionated cytoplasmic and
nuclear extracts were prepared from carefully dissected brain areas of P120
mice and CDKL5 levels determined by Western blotting using MeCP2 and
GAPDH as nuclear and cytoplasmic markers (upper,middle, and lower panels,
respectively). B, graphic illustration showing the relative levels of cytoplasmic
and nuclear CDKL5 (gray and black bars, respectively) in the different brain
areas. Hip., hippocampus; Ctx, cortex; Hyp., hypothalamus; Th., thalamus; Str.,
striatum; Cer., cerebellum. The band intensities in A were quantified using a
KODAK Image Station 2000R and the sum of cytoplasmic and nuclear CDKL5
set arbitrarily to 100%.
FIGURE 6. The nuclear localization of CDKL5 is induced at early postnatal
stages of the developing mouse brain. A, fractionated cytoplasmic and
nuclear extracts were prepared from total brains of E18, P2, P5, P14, P28, and
P120mice and relative levels of CDKL5 andMeCP2 analyzed byWestern blot-
ting (upper andmiddle panels, respectively). Actinwas used as loading control
(lower panels). B, graphic illustration showing the relative cytoplasmic and
nuclear levels (gray and black bars, respectively) of CDKL5 (left) and MeCP2
(right). The band intensities in Awere quantifiedwith a KODAK Image Station
2000R and the sum of cytoplasmic and nuclear fractions set arbitrarily to
100%.
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experiments revealed that the two genes have partially overlap-
ping expression patterns that are simultaneous activated during
development (11). Our studies, based on a polyclonal anti-
CDKL5 antibody purified against the antigen confirm these
data but provide a more detailed comprehension of the tempo-
ral and spatial expression pattern of the two proteins. At the
regional level, we detected both proteins in all the main brain
areas of adult mice by immunohistochemistry and Western
blotting in accordance with the hypothesis that they act in a
common molecular pathway. However, the two proteins seem
to differ with respect to onset of expression as well as their
relative abundance. In fact, MeCP2 is induced during embryo-
genesis and its levels remain rather constant during postnatal
stages until adulthood. CDKL5 levels, on the other hand, are
very low in the embryonic brain and are strongly induced dur-
ing the first two postnatal weeks in accordance with a possible
role of the protein in neuronal mat-
uration as in the case of MeCP2.
Moreover, CDKL5 levels also vary
significantly at the regional level in
the brain of adult mice. The highest
levels were observed in cortex, hip-
pocampus, and striatum whereas
very low levels were found in the
cerebellum, which on the other
hand is characterized by high levels
of MeCP2. It is interesting to note,
though, that MeCP2 levels increase
significantly in the cerebellum con-
comitantly with CDKL5 induction.
The apparent difference in themod-
ulation of CDKL5 andMeCP2 levels
probably reflects the distinct func-
tions of the two proteins, one being
a kinase and the other a chromatin-
binding protein. At the cellular
level, we could detect CDKL5 in all
mature NeuN-positive neurons.
In cultured primary neurons we
detectedCDKL5 in glutamatergic as
well as GABAergic neurons (data
not shown). In the adult mouse
brain, however, we observed that
GABAergic neurons in the hip-
pocampus and also Purkinje cells
seem to express higher levels of
CDKL5 raising the possibility that
the kinase plays a specific role in this
neuronal subtype. The only cells in
which we noted a significant differ-
ence in CDKL5 andMeCP2 expres-
sion were cultured astrocytes; in
fact, whereas CDKL5 was virtually
undetectable, we could detect low
but significant levels of MeCP2 in
accordance with a recent publica-
tion (36).
Our immunofluorescence exper-
iments on cultured cortical neurons showed that CDKL5 is
localized in both of the twomain cellular compartments. Inter-
estingly, cytoplasmic CDKL5 appears in the dendritic branches
with a distinct punctuate staining. The dendritic localization of
the kinase is in accordance with the overlap between CDKL5-
andMAP2-positive branches in the striatumof the adultmouse
brain and raises the possibility thatCDKL5might be involved in
transmitting signals from the synaptic branches to the cell
nucleus or vice versa. An interesting feature of CDKL5 that
distinguishes it fromMeCP2 is themodulation of its subcellular
distribution at the regional and temporal level. By Western
blotting we observed an almost even distribution of CDKL5
between the nucleus and cytoplasm in cortex, hypothalamus,
and thalamus, whereas a cytoplasmic accumulation was
detected in cerebellum and striatum. It is noteworthy that
CDKL5 seems to be excluded from the cell nucleus at the initial
FIGURE 7. The C-terminal regionmediates LMB-sensitive cytoplasmic localization of CDKL5. A, CDKL5, or
the indicated derivatives, were fused to GFP, transiently overexpressed in human HeLa cells, and the subcel-
lular localization analyzed 16 h after transfection. Right panels show the subcellular distribution in cells treated
with 50 mM LMB for 3 h. DAPI was used to stain the nuclei of fixed cells. B, two CDKL5 derivatives carrying RTT
causing truncating mutations were fused to GFP and their subcellular localization analyzed in HeLa cells.
C, schematic illustration of the CDKL5 derivatives used in the above experiments. All derivatives carried GFP in
the N terminus. Scale bar& 10 "m.
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stages of expression and becomes nuclear only during early
postnatal stages concomitantly with the strong induction of
expression correlating with neuronal maturation. We suspect
that CDKL5 exerts its most relevant functions in the cell
nucleus and that its localization in this cell compartment is
tightly regulated. This seems to be supported by the distribu-
tion of the protein in the cerebellum where its abundance is
very low and its localizationmainly restricted to the cytoplasm.
The spatial and temporal variation in the ratio between
nuclear and cytoplasmic CDKL5 suggests that its functions
might bemodulated throughmechanisms regulating its subcel-
lular localization. In accordance with this we show that the
C-terminal region of human CDKL5 is important for localizing
the protein properly in overexpressing cells. In fact, a GFP-
CDKL5 fusion protein was localized in both the cytoplasm and
the nucleus in most HeLa cells expressing the protein, whereas
a truncated protein, GFP-$831, was almost entirely nuclear in
all cells. Moreover, the partial cytoplasmic localization of the
full-length protein depends on nuclear export mediated by the
CRM1 nuclear export receptor, illustrated by the accumulation
of GFP-CDKL5 into the nucleus of cells treated with the CRM1
inhibitor LMB. Whether this is due to a direct interaction
between CDKL5 and CRM1 or an indirect mechanism is not
clear yet. The C-terminal region, required for the cytoplasmic
localization of CDKL5, contains a leucine-rich sequence, posi-
tioned at 836–845, resembling the consensus NES shown to be
the target of CRM1; however, this signal alone is not sufficient
for driving a heterologous protein, GFP, to the cytoplasm, and,
moreover, the mutagenesis of three leucines into alanines did
not alter the subcellular localization of the protein suggesting
that other signalsmight be involved.Moreover, the dynamics of
the nuclear accumulation of CDKL5 upon LMB treatment is
rather slow raising the possibility that an indirect mechanism
might be responsible for driving the kinase out of the nucleus.
The entry of CDKL5 into the nucleus probably depends on
two NLS-like stretches of basic amino acids within the long tail
of the protein. ThemostN-terminalNLS, from312–315, seems
to be sufficient for driving the CDKL5 R781X derivative to the
nucleus and the more C-terminal, located at 784–789, is suffi-
cient for nuclear import of a GFP fusion protein (data not
shown). Eventually, our previous results and data not shown
clearly indicate a role of the catalytic activity of CDKL5 for its
nuclear accumulation (29).
Considering all above, we suggest that the actual localization
of CDKL5 in a given cell depends on the balance between
nuclear import and export, direct or indirect, of the protein.We
are inclined toward a model where CDKL5 enzymatic activity
and the C-terminal tail are necessary to finely tune its dynamic
subcellular distribution. Even though future experiments will
lead to a detailedmolecular model, we propose that the confor-
mation of CDKL5 as well as its interaction with other proteins
both modulated by phosphorylation, are involved. We believe
that also the physiological state of the cell is important for
determining the final outcome. Accordingly, as mentioned
above, our immunofluorescence experiments demonstrate that
even though most of GFP-CDKL5 was contained in both com-
partments, some cells were characterized by an either exclu-
sively nuclear or cytoplasmic staining. We believe that various
signalingmechanisms, which are still unknown, are involved in
modulating the accessibility of CDKL5 to its substrates and that
the disruption of this regulation might be detrimental for neu-
ronal function. Besides MeCP2, no substrates of CDKL5 have
been identified and only future experiments will reveal whether
the kinase has targets also in the cytoplasm (11, 29).
In this work, we have demonstrated a role of the C-terminal
region of CDKL5 in regulating the shuttling of the protein
between the nucleus and the cytoplasm. Previously, the C ter-
minus has been shown to influence negatively the catalytic
activity of CDKL5 (29, 40). Altogether, it appears that this
region exerts multiple regulatory functions on the protein in
accordance with the fact that disease-causing mutations trun-
cating the protein prematurely have severe consequences for
neuronal functions. The two RTT CDKL5 derivatives that we
have analyzed, R781X and L879X, are both mislocalized to the
cell nucleus and are both characterized by an increase in auto-
catalytic activity (29).4 We therefore suggest that their consti-
tutive localization and the increased kinase activitymightmake
them behave as gain of function mutations. Even if attempts to
draw a genotype-phenotype correlation have not been able to
give clear results, it has recently been suggested that missense
mutations negatively affecting the catalytic activity of CDKL5
are associated with a more severe clinical picture than that
caused by late truncating mutations (10, 39). Based on our
results we therefore propose that the absence or reduction of
CDKL5 kinase functions have a greater impact on the nervous
system than a gain of activity.
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